GOLDSMITH MARK A

SEC source: 0001562180-21-004981 · primarydocument.xml · derivative · entry 7

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,171 shares

Expires not disclosed

F2 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

SEC source: 0001562180-21-004981 · primarydocument.xml · derivative · entry 6

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,083 shares

Expires not disclosed

F2 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

SEC source: 0001562180-21-004981 · primarydocument.xml · derivative · entry 5

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,446 shares

Expires not disclosed

F2 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

SEC source: 0001562180-21-004981 · primarydocument.xml · derivative · entry 4

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,171 shares

Expires not disclosed

F2 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

SEC source: 0001562180-21-004981 · primarydocument.xml · derivative · entry 3

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,825 shares

Expires not disclosed

F2 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

SEC source: 0001562180-21-004981 · primarydocument.xml · derivative · entry 2

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,171 shares

Expires not disclosed

F2 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

SEC source: 0001562180-21-004981 · primarydocument.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

SEC source: 0001567619-21-012488 · doc1.xml · nonDerivative · entry 5

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,003

F4 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.

F8 · price: This transaction was executed in multiple trades in prices ranging from $34.44 to $34.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F6 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2021.

F7 · balance_after: Includes 45,000 RSUs.

SEC source: 0001567619-21-012488 · doc1.xml · nonDerivative · entry 4

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,023

F4 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.

F5 · price: This transaction was executed in multiple trades in prices ranging from $33.44 to $34.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F6 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2021.

F7 · balance_after: Includes 45,000 RSUs.

SEC source: 0001562180-21-004076 · primarydocument.xml · derivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,171

Underlying: Common Stock · 13,171 shares

Expires 2031-06-01

F1 · derivative.exercise_date: This option was granted on June 2, 2021, and the shares underlying the option vest in equal quarterly installments through June 2, 2022, subject to continued service.

SEC source: 0001562180-21-002077 · primarydocument.xml · derivative · entry 3

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,987 shares

Expires 2021-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Shares are fully vested.

SEC source: 0001562180-21-002077 · primarydocument.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-005849 · doc1.xml · derivative · entry 5

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,000

Underlying: Common Stock · 169,000 shares

Expires 2031-03-03

F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 4, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001567619-21-005849 · doc1.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,744

F1 · balance_after: Includes 48,000 Restricted Stock Units.

SEC source: 0001567619-21-005602 · doc1.xml · derivative · entry 6

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,486

Underlying: Common Stock · 5,000 shares

Expires 2028-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F9 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001567619-21-005602 · doc1.xml · nonDerivative · entry 2

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 744

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $45.51 to $46.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001567619-21-005602 · doc1.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,744

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001567619-21-002501 · doc1.xml · derivative · entry 6

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,486

Underlying: Common Stock · 15,000 shares

Expires 2028-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F6 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001567619-21-002501 · doc1.xml · nonDerivative · entry 2

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 744

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020.

SEC source: 0001567619-21-002501 · doc1.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,744

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020.

SEC source: 0001567619-21-002063 · doc1.xml · derivative · entry 7

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,486

Underlying: Common Stock · 5,000 shares

Expires 2028-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F11 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001567619-21-002063 · doc1.xml · nonDerivative · entry 3

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 744

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The transaction was executed in multiple trades in prices ranging from $46.04 to $46.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020.

SEC source: 0001567619-21-002063 · doc1.xml · nonDerivative · entry 2

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,544

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The transaction was executed in multiple trades in prices ranging from $45.00 to $45.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020.

SEC source: 0001567619-21-002063 · doc1.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,744

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020.

SEC source: 0001562180-21-002076 · primarydocument.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee

Disclosed balance after: 74,870

F1 · kind: Consists of 64,173 shares transferred from The Goldsmith Midler 2002 Revocable Living Trust, of which Dr. Goldsmith is a trustee, to the Goldsmith and Midler Family Legacy Trust f/b/o Jonathan H. Goldsmith for 32,087 shares and the Goldsmith and Midler Family Legacy Trust f/b/o Rebecca E. Goldsmith for 32,087 shares.

SEC source: 0001562180-20-007466 · primarydocument.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee

Disclosed balance after: 139,043

F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001567619-21-002063 · doc1.xml · nonDerivative · entry 6

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 247,093

F8 · shares: This transaction involved a gift of securities by the Reporting Person.

F9 · balance_after: On December 2, 2020, Third Rock Ventures GP III, L.P. distributed 245 shares to the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust through an in-kind, pro rata distribution without value. This distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9.

F10 · ownership.nature: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

SEC source: 0000899243-21-003337 · doc5.xml · nonDerivative · entry 2

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee

Disclosed balance after: 139,043

F1 · kind: Consists of 2,000 shares transferred from The Goldsmith Midler 2002 Revocable Living Trust, of which Dr. Goldsmith is a trustee, to The Goldsmith Children 2011 Irrevocable Educational Trust, of which Dr. Goldsmith is a trustee.

SEC source: 0000899243-21-003337 · doc5.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee

Disclosed balance after: 139,043

F1 · kind: Consists of 2,000 shares transferred from The Goldsmith Midler 2002 Revocable Living Trust, of which Dr. Goldsmith is a trustee, to The Goldsmith Children 2011 Irrevocable Educational Trust, of which Dr. Goldsmith is a trustee.

SEC source: 0001567619-20-017292 · doc1.xml · derivative · entry 17

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,486

Underlying: Common Stock · 30 shares

Expires 2028-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F12 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001567619-20-017292 · doc1.xml · derivative · entry 16

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 520,841

Underlying: Common Stock · 42,548 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F11 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 11

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 71,879

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F8 · price: The transaction was executed in multiple trades in prices ranging from $34.03 to $34.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 10

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F7 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 9

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,578

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 8

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,548

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001567619-20-017292 · doc1.xml · derivative · entry 15

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 563,389

Underlying: Common Stock · 20,076 shares

Expires 2029-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F11 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001567619-20-017292 · doc1.xml · derivative · entry 14

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 331,229

Underlying: Common Stock · 10,447 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F10 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 7

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 73,191

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.56, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 6

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 5

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,523

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 4

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,447

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001567619-20-017292 · doc1.xml · derivative · entry 13

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,676

Underlying: Common Stock · 10,132 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F10 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 3

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 94,279

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.3750, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 2

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-20-017292 · doc1.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,132

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001567619-20-017065 · doc1.xml · derivative · entry 13

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 351,808

Underlying: Common Stock · 100 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F6 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001567619-20-017065 · doc1.xml · nonDerivative · entry 9

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 101,779

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust.

SEC source: 0001567619-20-017065 · doc1.xml · nonDerivative · entry 8

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001567619-20-017065 · doc1.xml · nonDerivative · entry 7

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001567619-20-017065 · doc1.xml · derivative · entry 12

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 351,908

Underlying: Common Stock · 10,097 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F6 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 13, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.